Agenus competitors

PHARMACEUTICAL EXECUTIVE WITH GLOBAL IMPACTIncreasing stakeholder value and meeting the needs of patients around the world.For over 25 years, I have increased profits and expanded market share for organizations in the pharmaceutical industry-from “big pharma” corporations to small biotech firms. Starting out in sales, I advanced over time to President of Bayer’s U.S. Pharmaceuticals organization. I currently serve as President and CEO of Acceleron Pharma, a public company.My work as an operations and commercial executive spans geographical regions, drug classes (small molecules, biologics), and therapeutic areas, including cardiovascular disease, hematology, neurology, neuromuscular, oncology, ophthalmology, pulmonary, and women’s health. Year after year, my teams have broken new ground by launching blockbuster brands, penetrating new markets, and outperforming sales expectations in competitive regions. Career Highlights:● Propelled Acceleron to a new stage of growth and shareholder value by pivoting the formerly research-focused company toward innovation and pre-commercialization. Increased stock performance vs the biotech index in 2017 & 2018, and positioned the company to potentially launch its first blockbuster drug in 2019.● Structured international organizations and revitalized teams, operations, and brand perceptions to navigate industry changes and exceed performance goals for Bayer AG.● Negotiated deals, such as the agreement between Bayer and Orion Corporation; managed partnerships including Genzyme, Orion Corporation, and Regeneron Pharmaceuticals.● Launched billion-dollar products, including Eylea®, Stivarga®, and Xofigo®, and positioned mature brands such as Betaferon®, Kogenate®, and Nexavar® for heightened success.I attribute my success to the determination, expertise, and hard work of my teams. It is a true privilege to work together in the quest to develop patient-centric organizations that deliver life-changing medications globally.

Ron Cohen, M.D., President and Chief Executive Officer, founded Acorda Therapeutics, Inc. in 1995. Previously he was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp. He previously served as Director and Chairman of the New York Biotechnology Association (NYBA). He also serves as a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service. Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year and was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. He is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by the New York Biotechnology Association as the NYBA “The Cure Starts Here” Business Leader of the Year.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Mr. Sunil Bhonsle, M.B.A has been the President of Titan Pharmaceuticals Inc. since 2009 and serves as its Principal Executive Officer, Principal Financial Officer and Secretary. Mr. Bhonsle served as Executive Vice President and Chief Operating Officer of Titan Pharmaceuticals Inc. since September 1995. Mr. Bhonsle served as Vice President and General Manager-Plasma Supply and Manager-Inventory and Technical Planning, of Bayer Corporation From July 1975 to April 1995. He has been a Director of Titan Pharmaceuticals Inc., since February 2004. He Holds an MBA from the University of California at Berkeley and a B.Tech. in Chemical Engineering from The Indian Institute of Technology.

John Simard is a Chairman/President/CEO/Founder at XBiotech USA Inc, VP/Founder at MANNKIND CORP, and Board Member at MANNKIND CORP. He attended University of Toronto.

Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA). Joined XOMA in 2009 and was appointed to the CEO role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow. In addition to his role at XOMA, Mr. Neal currently serves as a Director at Leading Biosciences, a clinical stage biotech company based in Carlsbad, CA. Mr. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.

Skip Wagner is a President and Chief Executive Officer at BioReliance and is based in College Station, Texas.